|
Agios Pharmaceuticals, Inc. (AGIO) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Agios Pharmaceuticals, Inc. (AGIO) Bundle
Explore Agios Pharmaceuticals, Inc. (AGIO) Finanzielle Zukunft mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Prognosen für Wachstum, Margen und Ausgaben ein, um Agios Pharmaceuticals, Inc. (AGIO) Intrinsischer Wert zu berechnen und Ihren Investitionsansatz zu gestalten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 203.2 | .0 | 14.2 | 26.8 | 36.5 | 38.7 | 41.1 | 43.6 | 46.3 | 49.1 |
| Revenue Growth, % | 0 | -100 | 0 | 88.36 | 36.07 | 6.11 | 6.11 | 6.11 | 6.11 | 6.11 |
| EBITDA | -326.1 | -337.7 | -380.5 | -384.9 | -425.7 | -23.2 | -24.7 | -26.2 | -27.8 | -29.5 |
| EBITDA, % | -160.5 | 100 | -2671.93 | -1434.83 | -1166.47 | -60 | -60 | -60 | -60 | -60 |
| Depreciation | 18.8 | 18.8 | 18.6 | 6.6 | .0 | 18.1 | 19.2 | 20.4 | 21.6 | 23.0 |
| Depreciation, % | 9.24 | 100 | 130.33 | 24.69 | 0 | 46.79 | 46.79 | 46.79 | 46.79 | 46.79 |
| EBIT | -344.9 | -356.5 | -399.0 | -391.5 | -425.7 | -23.2 | -24.7 | -26.2 | -27.8 | -29.5 |
| EBIT, % | -169.74 | 100 | -2802.26 | -1459.52 | -1166.47 | -60 | -60 | -60 | -60 | -60 |
| Total Cash | 670.5 | 1,286.4 | 1,097.0 | 776.9 | 893.7 | 38.7 | 41.1 | 43.6 | 46.3 | 49.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 4.4 | 2.2 | 2.8 | 4.1 | 10.6 | 11.3 | 12.0 | 12.7 | 13.5 |
| Account Receivables, % | 0 | 100 | 15.49 | 10.48 | 11.26 | 27.45 | 27.45 | 27.45 | 27.45 | 27.45 |
| Inventories | 14.7 | 16.2 | 8.5 | 19.1 | 27.6 | 24.3 | 25.8 | 27.4 | 29.0 | 30.8 |
| Inventories, % | 7.23 | 100 | 59.63 | 71.12 | 75.66 | 62.73 | 62.73 | 62.73 | 62.73 | 62.73 |
| Accounts Payable | 17.7 | 16.7 | 18.6 | 9.8 | 16.6 | 22.5 | 23.9 | 25.4 | 26.9 | 28.6 |
| Accounts Payable, % | 8.72 | 100 | 130.73 | 36.46 | 45.6 | 58.16 | 58.16 | 58.16 | 58.16 | 58.16 |
| Capital Expenditure | -14.9 | -5.7 | -4.9 | -1.0 | -1.7 | -3.9 | -4.1 | -4.4 | -4.6 | -4.9 |
| Capital Expenditure, % | -7.34 | 100 | -34.28 | -3.72 | -4.62 | -9.99 | -9.99 | -9.99 | -9.99 | -9.99 |
| Tax Rate, % | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 | 6.16 |
| EBITAT | -353.2 | 1,604.7 | -128.3 | -391.5 | -399.5 | -15.2 | -16.1 | -17.1 | -18.1 | -19.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -346.3 | 1,610.9 | -102.9 | -405.9 | -404.2 | 1.8 | -1.7 | -1.8 | -1.9 | -2.0 |
| WACC, % | 8.05 | 7.94 | 7.98 | 8.05 | 8.05 | 8.02 | 8.02 | 8.02 | 8.02 | 8.02 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -4.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -35 | |||||||||
| Present Terminal Value | -24 | |||||||||
| Enterprise Value | -28 | |||||||||
| Net Debt | -19 | |||||||||
| Equity Value | -8 | |||||||||
| Diluted Shares Outstanding, MM | 58 | |||||||||
| Equity Value Per Share | -0.15 |
What You Will Get
- Comprehensive AGIO Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Agios Pharmaceuticals' future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Agios Pharmaceuticals, Inc. (AGIO).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to AGIO.
- Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates for accurate projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Agios Pharmaceuticals, Inc. (AGIO).
- Interactive Dashboard and Charts: Visual representations provide a summary of key valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Agios Pharmaceuticals data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Agios Pharmaceuticals’ intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Agios Pharmaceuticals, Inc. (AGIO)?
- Designed for Industry Experts: A sophisticated tool utilized by researchers, financial analysts, and healthcare consultants.
- Comprehensive Data: Agios's historical and projected financials are preloaded for enhanced precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly Interface: Step-by-step guidance simplifies the calculation process.
Who Should Use This Product?
- Investors: Evaluate Agios Pharmaceuticals' valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation processes and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech companies like Agios.
- Consultants: Provide detailed valuation reports and insights for clients in the pharmaceutical sector.
- Students and Educators: Utilize real-world data from Agios to learn and teach valuation methodologies.
What the Template Contains
- Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Agios Pharmaceuticals, Inc. (AGIO).
- Real-World Data: Agios Pharmaceuticals' historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into Agios Pharmaceuticals' performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Agios Pharmaceuticals, Inc. (AGIO).
- Dashboard with Visual Outputs: Charts and tables that provide clear, actionable results for informed decision-making.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.